Evidence map›Paper›PMID 38129572›Full record

ArticleCommunications biology2023

Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia.

Emi Sugimoto, Jingmei Li, Yasutaka Hayashi, Kohei Iida, Shuhei Asada, Tsuyoshi Fukushima, Moe Tamura, Shiori Shikata, Wenyu Zhang, Keita Yamamoto and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Emi Sugimoto *Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Jingmei Li *Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Yasutaka HayashiDivision of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kohei IidaDivision of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Shuhei AsadaDivision of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-6116-7996
Tsuyoshi FukushimaDivision of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Moe TamuraDivision of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Shiori ShikataDivision of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Wenyu ZhangDivision of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Keita YamamotoDivision of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Kimihito Cojin KawabataDivision of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tatsuya KawaseDrug Discovery Research, Astellas Pharma, Ibaraki, Japan.
Takeshi SaitoClinical Pharmacology Exploratory Development, Astellas Pharma, Westborough, MA, USA.
Taku YoshidaDrug Discovery Research, Astellas Pharma, Ibaraki, Japan.
Satoshi YamazakiLaboratory of Stem Cell Therapy, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.ORCID 0000-0003-4249-3854
Yuta KaitoDepartment of Hematology/Oncology, IMSUT Hospital, The University of Tokyo, Tokyo, Japan.
Yoichi ImaiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Tamami DendaDepartment of Pathology, The Institute of Medical Science Research Hospital, The University of Tokyo, Tokyo, Japan.
Yasunori OtaDepartment of Pathology, The Institute of Medical Science Research Hospital, The University of Tokyo, Tokyo, Japan.
Tomofusa FukuyamaDivision of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-0709-3188
Yosuke TanakaDivision of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-8538-0916
Yutaka EnomotoDivision of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Toshio KitamuraDivision of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. kitamura@ims.u-tokyo.ac.jp.ORCID 0000-0001-7855-1767
Susumu GoyamaDivision of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. goyama@edu.k.u-tokyo.ac.jp.ORCID 0000-0002-9339-1826

Funding

Japan Agency for Medical Research and Development (AMED) 21ck0106644h0001Japan Agency for Medical Research and Development (AMED) 22ama221514s0201MEXT | Japan Society for the Promotion of Science (JSPS) 19H03685MEXT | Japan Society for the Promotion of Science (JSPS) 20H00537MEXT | Japan Society for the Promotion of Science (JSPS) 22H03100MEXT | Japan Society for the Promotion of Science (JSPS) 22K19540
6 · The paper itself

Abstract

Immunotherapy has attracted considerable attention as a therapeutic strategy for cancers including acute myeloid leukemia (AML). In this study, we found that the development of several aggressive subtypes of AML is slower in Rag2

Indexed as

Killer Cells, NaturalLeukemia, Myeloid, AcuteAnimalsDNA-Binding ProteinsMiceMice, Inbred C57BLMice, KnockoutT-LymphocytesDNA-Binding ProteinsRag2 protein, mouse

Identifiers

PMID38129572
PMCPMC10739813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.